Tubular and glomerular injury in diabetes and the impact of ACE inhibition

Diabetes Care

Volumn 32, Issue 9, 2009, Pages 1684-1688

  Nielsen, Stine E ^a   Sugaya, Takeshi ^b   Tarnow, Lise ^a   Lajer, Maria ^a   Schjoedt, Katrine J ^a   Astrup, Anne Sofie ^a   Baba, Tsuneharu ^c   Parving, Hans Henrik ^d,e   Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

^b RIKEN KOBE INSTITUTE   (Japan)

^c Hiroshima Prefectural Univ   (Japan)

^d AARHUS UNIVERSITY   (Denmark)

^e International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID BINDING PROTEIN; LISINOPRIL;

ADULT; ALBUMINURIA; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GLOMERULAR DYSFUNCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TUBULAR DYSFUNCTION;

ADULT; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED;

EID: 69549135319     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0429     Document Type: Article

References (25)

1. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-1264 (Pubitemid 36929282)
2. Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In Brenner & Rector's The Kidney. 8th ed. Brenner BM, Ed. Boston, WB Saunders, 2008, p. 1265-1298
3. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Br Med J 2004;328: 1105 (Pubitemid 38608441)
4. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56: 1627-1637
5. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the hearttype fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288(Pt. 1):285-290
6. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165: 1243-1255 (Pubitemid 39297730)
7. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006;284: 175-182 (Pubitemid 44404425)
8. Zimmerman AW, Veerkamp JH. Fattyacid- binding proteins do not protect against induced cytotoxicity in a kidney cell model. Biochem J 2001;360:159-165
9. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-516 (Pubitemid 24133655)
10. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008;19:1283-1290
11. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van LF. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254
12. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005; 28:2728-2732 (Pubitemid 43951167)
13. Schjoedt KJ, Astrup A-S, Persson F, Frandsen E, Boomsma F, Rossing K, Tarnow L, Rossing P, Parving H-H. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy. Diabetologia 2009;52:46-49
14. Suzuki K, Babazono T, Murata H, Iwamoto Y. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. Diabetes Care 2005;28:2038-2039 (Pubitemid 41060984)
15. Mayer G, Cerritto l, Sugaya T. Urinary- LFABP: a novel biomarker for renal disease and its role in the diagnosis and prognosis of chronic and acute kidney disease. Fats Life 2008;10:4-11
16. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M. Urinary fatty acidbinding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23-30 (Pubitemid 38156413)
17. Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008;4:216-226
18. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005; 145:125-133 (Pubitemid 40432361)
19. Parving H-H, Noer I, Deckert T, Evrin P-E, Nielsen SL, Lyngsøe J, Mogensen CE, Rørth M, Svendsen PA, Trap-Jensen J, Lassen NA. The effect of metabolic regulation on microvascular permeability to small and large molecules in short-term juvenile diabetics. Diabetologia 1976;12: 161-166
20. Ekstrom B, Peterson PA, Berggard I. Urinary and plasma α-1-glycoprotein of lowmolecular weight: isolation and some properties. Biochem Biophys Res Commun 1975;65:1427-1433
21. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins-review. Kidney Int 1979;16: 251-270
22. Yu H, Yanagisawa Y, Forbes MA, Cooper EH, Crockson RA, Maclennan ICM. α-1- Microglobulin - an indicator protein for renal tubular function. J Clin Pathol 1983; 36:253-259 (Pubitemid 13160686)
23. Nakamura T, Sugaya T, Koide H. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia 2007;50:490-492
24. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002;61:31-39 (Pubitemid 34075128)
25. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de SC, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005;16:3631-3641 (Pubitemid 46211284)